Patient Recruitment Resumes in FibroGen Phase 2 Study of Investigational Oral HIF-PH Inhibitor, FG-4592/ASP1517, for ... (Business Wire via Yahoo! Finance) PDF Print

SAN FRANCISCO----FibroGen, Inc. today announced that patient recruitment has resumed in a phase 2 study of FG-4592/ASP1517, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor in development for the treatment of anemia associated with chronic kidney disease .

read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.